Walling H W, Chan P T, Omura T H, Barmina O Y, Fiacco G J, Jeffrey J J, Partridge N C
Department of Pharmacological and Physiological Science, Saint Louis University Health Sciences Center, Missouri 63104, USA.
J Cell Physiol. 1998 Dec;177(4):563-74. doi: 10.1002/(SICI)1097-4652(199812)177:4<563::AID-JCP7>3.0.CO;2-B.
We have previously described a specific, saturable receptor for rat collagenase-3 in the rat osteosarcoma cell line, UMR 106-01. Binding of rat collagenase-3 to this receptor is coupled to the internalization and eventual degradation of the enzyme and correlates with observed extracellular levels of the enzyme. In this study we have shown that decreased binding, internalization, and degradation of 125I-rat collagenase-3 were observed in cells after 24 h of parathyroid hormone treatment; these activities returned to control values after 48 h and were increased substantially (twice control levels) after 96 h of treatment with the hormone. Subcellular fractionation studies to identify the route of uptake and degradation of collagenase-3 localized intracellular accumulation of 125I-rat collagenase-3 initially in Golgi-associated lysosomes and later in secondary lysosomes. Maximal lysosomal accumulation of the radiolabel and stimulation of general lysosomal activity occurred after 72 h of parathyroid hormone treatment. Preventing fusion of endosomes with lysosomes (by temperature shift, colchicine, or monensin) resulted in no internalized 125I-collagenase-3 in either lysosomal fraction. Treatment of UMR cells with the above agents or ammonium chloride decreased excretion of 125I-labeled degradation products of collagenase-3. These experiments demonstrated that degradation of collagenase-3 required receptor-mediated endocytosis and sequential processing by endosomes and lysosomes. Thus, parathyroid hormone regulates the expression and synthesis of collagenase-3 as well as the abundance and functioning of the collagenase-3 receptor and the intracellular degradation of its ligand. The coordinate changes in the secretion of collagenase-3 and expression of the receptor determine the net abundance of the enzyme in the extracellular space.
我们之前已描述过,在大鼠骨肉瘤细胞系UMR 106-01中存在一种针对大鼠胶原酶-3的特异性、可饱和受体。大鼠胶原酶-3与该受体的结合与酶的内化及最终降解相关联,且与所观察到的该酶细胞外水平相关。在本研究中,我们发现甲状旁腺激素处理24小时后,细胞中125I-大鼠胶原酶-3的结合、内化及降解均减少;48小时后这些活性恢复至对照值,而在激素处理96小时后显著增加(为对照水平的两倍)。亚细胞分级分离研究用于确定胶原酶-3的摄取和降解途径,结果显示125I-大鼠胶原酶-3最初在高尔基体相关溶酶体中出现细胞内积累,随后出现在次级溶酶体中。甲状旁腺激素处理72小时后,放射性标记在溶酶体中的积累达到最大值,且一般溶酶体活性受到刺激。通过温度变化、秋水仙碱或莫能菌素阻止内体与溶酶体融合,导致两个溶酶体组分中均无内化的125I-胶原酶-3。用上述试剂或氯化铵处理UMR细胞可减少胶原酶-3的125I标记降解产物的排泄。这些实验表明,胶原酶-3的降解需要受体介导的内吞作用以及内体和溶酶体的顺序加工。因此,甲状旁腺激素调节胶原酶-3的表达和合成,以及胶原酶-3受体的丰度和功能及其配体的细胞内降解。胶原酶-3分泌和受体表达的协同变化决定了细胞外空间中该酶的净丰度。